Icra sees pharma industry growth tapering to 7-10% over FY18-FY20Post published:July 4, 2017Post category:Industry NewsThe Indian pharma industry is likely to witness a slowdown in growth because of pricing pressure and regulatory interventions in the US, according to an Icra report Source: Livemint.com (http://www.livemint.com/rss/industry)Read more articles Previous PostIndoStar Capital close to acquiring ICICI Home Finance Next PostGST rates: Footwear to cost more as firms look to increase prices by 5-7% You Might Also Like Snap drops after trailing estimates for users, sales May 11, 2017 Overmatch Capability for the Warfighter: Thermal Vision and Infrared Imaging December 27, 2018 Donald Trump blamed for job losses as Indian IT workers face cuts May 24, 2017